Research and analysis

COVID-19: genomic surveillance of patients treated with neutralising monoclonal antibody or immunosuppressed

This protocol covers the surveillance of patients who are highly immunosuppressed, and all patients receiving therapeutic neutralising monoclonal antibodies.

• From: UK Health Security Agency and NHS England
• Published: 22 October 2021
• Last updated: 9 May 2022 — See all updates

This publication was withdrawn on 31 August 2023

The UK Health Security Agency (UKHSA) surveillance of the use of COVID-19 therapeutics in individuals who are eligible to receive them, and the potential resistance to therapeutics, was stood down on 31 August 2023.

Previous technical briefings are still available and annual updates via the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report will be provided.

This surveillance activity does not impact individuals’ eligibility or access to therapeutics. Please see the most recent government advice on eligibility for and access to COVID-19 therapeutics from Highest-risk patients eligible for new COVID-19 treatments: a guide for patients on GOV.UK.

Applies to England

Documents

[Withdrawn] Protocol: Surveillance of patients with COVID-19 who are treated with neutralising monoclonal antibodies or antivirals

Ref: UKHSA publications gateway number GOV-12186

PDF, 1.01 MB, 17 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

[Withdrawn] Help the NHS understand the impact of antiviral and antibody treatments for COVID-19

HTML

Details

The aims of this genomic surveillance programme are to:

• monitor for the development of SARS-CoV-2 mutations and variants in patients treated with therapeutic monoclonal antibodies and to describe which mutations emerge and at what frequency
• monitor for the development of SARS-CoV-2 mutations and variants in patients who are highly immunosuppressed, and to describe which mutations emerge and at what frequency
• monitor the outcomes of patients with coronavirus (COVID-19) who have received therapeutic monoclonal antibodies

Published 22 October 2021
Last updated 9 May 2022 + show all updates

1. 9 May 2022

   Added 'Protocol: Surveillance of patients with COVID-19 who are treated with neutralising monoclonal antibodies or antivirals' and supporting annexe.

2. 22 October 2021

   First published.